RE: Phase 3 Success Rate28 Jan 2026 09:45
Hi joaung1,
Yes, much higher chance of success, due to high statistically significant results in phase 1 & 2 that are a long way above standard of care.
Also, immunobody as a platform has been proven to be well tolerated, safe and effective in many patients over 3 trials (scib1 phase 1, covidity and scib1/iscib1+ phase 2).
Also, if you research Scancell and Lindy Durrant in particular, they are top of their game and have developed the Scancell platforms using science over hyperbole. If you have the kind of mind that can understand the tech, please do, because it is stunning!